Month: July 2022

Takeda_Red_Logo_2021

Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years

Children Ages 2 to <12 Experienced 94.8% Fewer Hereditary Angioedema (HAE) Attacks During Treatment with TAKHZYRO Over the 52-Week Treatment...